Capitalizing on a crisis: a computational analysis of all five million British firms during the Covid-19 pandemic
Muggleton N. et al, (2025), Journal of Computational Social Science, 8
Bayesian modelling of repeated cross-sectional epidemic prevalence survey data
Steyn N. et al, (2025)
Subpopulations in clinical samples ofM. tuberculosiscan give rise to rifampicin resistance and shed light on how resistance is acquired
Brunner VM. and Fowler PW., (2025)
The value of large-scale programmes in human genomics
Horn R. et al, (2025), European Journal of Human Genetics
Priorities for rapid and cost-effective vaccines to improve outbreak responses
Gilbert SC., (2025), PLOS Biology, 23, e3003114 - e3003114
Ethical considerations in the routine identification of human remains in forensic mortuaries
Reid KM. et al, (2025), Wellcome Open Research, 10, 171 - 171
A systems biology approach to define SARS-CoV-2 correlates of protection.
Brady C. et al, (2025), NPJ vaccines, 10
Acceptability of the gonorrhoea human challenge model to accelerate vaccine development in UK men
Firth C. et al, (2025), Vaccine, 54, 127013 - 127013
Call for a fairer approach to authorship in publishing biomedical research.
Cheah PY. and Parker M., (2025), Communications medicine, 5
Genetically distinct within-host subpopulations of hepatitis C virus persist after Direct-Acting Antiviral treatment failure
Zhao L. et al, (2025), PLOS Pathogens, 21, e1012959 - e1012959
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development.
Siegal EZ. et al, (2025), NPJ vaccines, 10
Silaproline-bearing nirmatrelvir derivatives are potent inhibitors of the SARS-CoV-2 main protease highlighting the value of silicon-derivatives in structure-activity-relationship studies.
Laczi D. et al, (2025), European journal of medicinal chemistry, 291
The overlapping global distribution of dengue, chikungunya, Zika and yellow fever.
Lim A. et al, (2025), Nature communications, 16
Comparative performance of novel viral landscape phylogeography approaches.
Dellicour S. et al, (2025)
Transformers and large language models are efficient feature extractors for electronic health record studies
Yuan K. et al, (2025), Communications Medicine, 5
Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimens.
Walker TM. et al, (2025), Lancet Infect Dis
Cases of high consequence infectious diseases identified in the UK, 1962–2023
Atkinson B. et al, (2025), Journal of Medical Microbiology, 74
Case series of the first five human infections with monkeypox virus clade Ib and report on the public health response, United Kingdom, October to November 2024
Alvi MI. et al, (2025), Eurosurveillance, 30
Research prioritisation in preparedness for and response to outbreaks of high-consequence pathogens: a scoping review
Antonio E. et al, (2025), BMC Medicine, 23
Single-cell profiling of blood and cerebrospinal fluid in tuberculous meningitis
Tram TTB. et al, (2025)
The Rare Therapies Launchpad: a pilot program for individualized medicines in the UK
O’Connor DJ. et al, (2025), Nature Medicine
Infrastructure, capabilities, and capacities required for clinical trials design and delivery: A rapid scoping review of recommendations and regulations
Merson L. et al, (2025), Wellcome Open Research, 9, 729 - 729
Breaking Bonds, Changing Habits: Understanding Health Behaviors during and after Marital Dissolution
Tilstra AM. and Kapelle N., (2025), Journal of Health and Social Behavior
Factors associated with death in patients admitted with Ebola virus disease to Ebola Treatment Units in Guinea, Sierra Leone, and Liberia – December 2013 to March 2016
Yeabah TO. et al, (2025), F1000Research, 13, 672 - 672
Editors' Note on Looking Backward, Looking Forward: Celebrating 50 Years of Population and Development Review
Muttarak R. and Wilde J., (2025), Population and Development Review
Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.
Mellors J. et al, (2025), Nature communications, 16
Compositional analysis of lymphocytes and their relationship with health outcomes: findings from the health and retirement study.
Xu L. et al, (2025), Immunity & ageing : I & A, 22
Confronting the shortcomings of covid-19 vaccination will help us in future pandemics.
Vanderslott S., (2025), BMJ (Clinical research ed.), 388
Ebola disease: bridging scientific discoveries and clinical application
Rojek A. et al, (2025), The Lancet Infectious Diseases, 25, e165 - e176
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Abani O. et al, (2025), eClinicalMedicine, 81, 103080 - 103080
Investigating the role of elastin and extracellular matrix damage in cardiovascular calcification
Radvar E. et al, (2025), Journal of Structural Biology, 217, 108140 - 108140
Production of an immunogenic trivalent poliovirus virus-like particle vaccine candidate in yeast using controlled fermentation.
Sherry L. et al, (2025), NPJ vaccines, 10
Socio-economic status is a social construct with heritable components and genetic consequences.
Abdellaoui A. et al, (2025), Nature human behaviour
A 5-transcript signature for discriminating viral and bacterial etiology in pediatric pneumonia
Viz-Lasheras S. et al, (2025), iScience, 28
Artificial intelligence for modelling infectious disease epidemics
Kraemer MUG. et al, (2025), Nature, 638, 623 - 635
Individualised Treatment Effects Estimation with Composite Treatments and Composite Outcomes
Chauhan VK. et al, (2025)
Status of Digital Health Technology Adoption in 5 Vietnamese Hospitals: Cross-Sectional Assessment
Tran DM. et al, (2025), JMIR Formative Research, 9, e53483 - e53483
A putative hepatitis B virus sequence motif associated with hepatocellular carcinoma in South African adults
Maponga TG. et al, (2025), Annals of Hepatology, 101763 - 101763
Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics.
Bourner J. et al, (2025), Emerging infectious diseases, 31, 9 - 16
An analysis of controlled human infection studies registered on ClinicalTrials.gov.
Toomey D. et al, (2025), BMJ open, 15